In trying to deliver breakthrough, Voyager is able to ink multiple robust deals with reputable companies. Read why the Neurocrine deal signals more upside for VYGR.
In late 2022, Vanda lost intellectual property protection of its flagship drug, Hetlioz.
See why I reduced my recommendation on VNDA stock from a buy to hold.
After the generic infringement debacle, Amarin transitioned from a growth stock to a turnaround play. See it can turn around with pressure from Sarissa Capital?
Sales for Bylvay's first approved indication is increasing. Albireo recently posted superb data for orphan disease known as Alagille Syndrome. Read more here.